Sequence variation among members of the miR-200 microRNA family is correlated with variation in the ability to induce hallmarks of mesenchymal-epithelial transition in ovarian cancer cells

Journal of Ovarian Research

John F McDonald²  Ashley N Reavis¹  Neda Jabbari¹ 

[1] School of Biology, Parker H. Petit Institute of Bioengineering and Biosciences, 315 Ferst Drive, Atlanta, GA 30332-0363, USA;Integrated Cancer Research Center, Georgia Institute of Technology, 315 Ferst Drive, Atlanta, GA 30332-0363, USA

关键词: MET;    EMT;    MicroRNAs;    Metastasis;    Ovarian cancer;   

Others  :  802095
DOI  :  10.1186/1757-2215-7-12

 received in 2013-12-18, accepted in 2014-01-15,  发布年份 2014

【 摘 要 】

Background

Epithelial-Mesenchymal Transition (EMT) is a transient and reversible (Mesenchymal-Epithelial Transition or MET) process by which epithelial cells acquire mesenchymal cell characteristics including reduced intercellular adhesion and increased cell motility. While EMT/MET has long been recognized as an essential component of early embryonic development, there is a growing body of evidence indicating that EMT/MET is also a key component of ovarian cancer (OC) metastasis. Recent findings have implicated members of the miR-200 family of microRNAs (miRNAs) in this process.

Methods

Individual members of the miR-200 family of miRNAs were transiently over expressed in metastatic (mesenchymal-like) OC cell lines. Changes in morphology, molecular profiles and drug sensitivity were monitored relative to cells transfected with a negative control.

Results

Morphological hallmarks of MET were detected in cells transfected with all miR-200 family members. Gene expression profiling demonstrated up regulation of epithelial biomarkers and down regulation of mesenchymal biomarkers in transfected cells although significant variation in molecular response and drug sensitivity was associated with different members of the miR-200 family.

Conclusions

Our results indicate that although ectopic overexpression of all members of the miR-200 family in mesenchymal-like OC cells results in morphological changes characteristic of MET, the underlying molecular changes and induced drug sensitivities are highly variable and correlated with sequence variation within the seed and non-seed regions of individual family members.

【 授权许可】

   
2014 Jabbari et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

【 参考文献 】

• [1]Siegel R, Ward E, Brawley O, Jemal A: Cancer statistics, 2011. CA Cancer J Clin 2011, 61:212-236.
• [2]Halkia E, Spiliotis J, Sugarbaker P: Diagnosis and management of peritoneal metastases from ovarian cancer. Gastroenterol Res Pract 2012, 2012:541842.
• [3]Huber MA, Kraut N, Beug H: Molecular requirements for epithelial–mesenchymal transition during tumor progression. Curr Opin Cell Biol 2005, 17:548-558.
• [4]Acloque H, Adams MS, Fishwick K, Bronner-Fraser M, Nieto MA: Epithelial-mesenchymal transitions: the importance of changing cell state in development and disease. J Clin Invest 2009, 119:1438-1449.
• [5]Brabletz T: To differentiate or not — routes towards metastasis. Nat Rev Cancer 2012, 12:425-436.
• [6]Chaffer CL, Thompson EW, Williams ED: Mesenchymal to epithelial transition in development and disease. Cells Tissues Organs 2007, 185:7-19.
• [7]Monteiro J, Fodde R: Cancer stemness and metastasis: therapeutic consequences and perspectives. Eur J Cancer 2010, 46:1198-1203.
• [8]Chen J, Wang L, Matyunina LV, Hill CG, McDonald JF: Overexpression of miR-429 induces mesenchymal-to-epithelial transition (MET) in metastatic ovarian cancer cells. Gyn Onc 2011, 121:200-205.
• [9]Gregory PA, Bert AG, Paterson EL, Barry SC, Tsykin A, Farshid G, Vadas MA, Khew-Goodall Y, Goodall GJ: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEB1 and SIP1. Nat Cell Biol 2008, 10:593-601.
• [10]Park S-M, Gaur AB, Lengyel E, Peter ME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEB1 and ZEB2. Genes Dev 2008, 22:894-907.
• [11]Carpenter A, Jones T, Lamprecht M, Clarke C, Kang I, Friman O, Guertin D, Chang J, Lindquist R, Moffat J, et al.: Cell Profiler: image analysis software for identifying and quantifying cell phenotypes. Gen Biol 2006, 7:R100. BioMed Central Full Text
• [12]Mills GB, May C, Hill M, Campbell S, Shaw P, Marks A: Ascitic fluid from human ovarian cancer patients contains growth factors necessary for intraperitoneal growth of human ovarian adenocarcinoma cells. J Clin Invest 1990, 86:851-855.
• [13]Fogh J, Fogh JM, Orfeo T: One hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J Natl Cancer Inst 1977, 59:221-226.
• [14]Zeisberg M, Neilson EG: Biomarkers for epithelial-mesenchymal transitions. J Clin Invest 2009, 119:1429-1437.
• [15]Bartel DP: MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 2004, 116:281-297.
• [16]Takeichi M: Cadherins: a molecular family important in selective cell-cell adhesion. Annu Rev Biochem 1990, 59:237-252.
• [17]Lewis BP, Shih I, Jones-Rhoades MW, Bartel DP, Burge CB: Prediction of mammalian microrna targets. Cell 2003, 115:787-798.
• [18]Betel D, Wilson M, Gabow A, Marks DS, Sander C: The microRNA.org resource: targets and expression. Nuc Acids Res 2008, 36:D149-D153.
• [19]Wang X: miRDB: A microRNA target prediction and functional annotation database with a wiki interface. RNA 2008, 14:1012-1017.
• [20]Lewis BP, Burge CB, Bartel DP: Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microrna targets. Cell 2005, 120:15-20.
• [21]Arumugam T, Ramachandran V, Fournier KF, Wang H, Marquis L, Abbruzzese JL, Gallick GE, Logsdon CD, McConkey DJ, Choi W: Epithelial to mesenchymal transition contributes to drug resistance in pancreatic cancer. Can Res 2009, 69:5820-5828.
• [22]Adam L, Zhong M, Choi W, Qi W, Nicoloso M, Arora A, Calin G, Wang H, Siefker-Radtke A, McConkey D, et al.: miR-200 expression regulates epithelial-to-mesenchymal transition in bladder cancer cells and reverses resistance to epidermal growth factor receptor therapy. Clin Cancer Res 2009, 15:5060-5072.
• [23]Shah A, Summy J, Zhang J, Park S, Parikh N, Gallick G: Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann of Surg Oncol 2007, 14:3629-3637.
• [24]Haslehurst A, Koti M, Dharsee M, Nuin P, Evans K, Geraci J, Childs T, Chen J, Li J, Weberpals J, et al.: EMT transcription factors snail and slug directly contribute to cisplatin resistance in ovarian cancer. BMC Cancer 2012, 12:91. BioMed Central Full Text
• [25]Marchini S, Fruscio R, Clivio L, Beltrame L, Porcu L, Nerini IF, Cavalieri D, Chiorino G, Cattoretti G, Mangioni C, et al.: Resistance to platinum-based chemotherapy is associated with epithelial to mesenchymal transition in epithelial ovarian cancer. Eur J Can 2013, 49:520-530.
• [26]Mehlen P, Puisieux A: Metastasis: a question of life or death. Nat Rev Cancer 2006, 6:449-458.
• [27]Bacac M, Stamenkovic I: Metastatic cancer cell. Annu Rev Path Mechs Dis 2008, 3:221-247.
• [28]Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA: SEER cancer statistics review, 1975-2010. [http://seer.cancer.gov/csr/1975_2010/ webcite]
• [29]Thiery JP: Epithelial-mesenchymal transitions in tumour progression. Nat Rev Cancer 2002, 2:442-454.
• [30]Vergara D, Merlot B, Lucot JP, Collinet P, Vinatier D, Fournier I, Salzet M: Epithelial-mesenchymal transition in ovarian cancer. Cancer Lett 2010, 291:59-66.
• [31]Lili LN, Matyunina LV, Walker LD, Wells SL, Benigno BB, McDonald JF: Molecular profiling supports the role of epithelial-to-mesenchymal transition (EMT) in ovarian cancer metastasis. J Ovar Res 2013, 6:49. BioMed Central Full Text
• [32]Xu H, Hui KM: MicroRNAs involved in regulating epithelial-mesenchymal transition and cancer stem cells as molecular targets for cancer therapeutics. Can Gene Ther 2012, 19:723-730.